Our findings provide the first evidence that blockade of PRs using antisense oligonucleotides induces inhibition of tumor growth, and provide further evidence for a critical involvement of the stimulatory effects of the PR pathway in mammary cancer, supporting its choice as an alternative therapeutic target for those tumors bearing receptors that are unable to bind ligands. The gene discussed is WNK3; the disease is breast cancer.